4D Molecular Therapeutics, Inc. 10-K filing
Filed 2026-03-18 · Report date 2025-12-31 · 2025 FY
Filing metadata
- Accession number
- 0001193125-26-114075
- Form type
- 10-K
- CIK
- 0001650648
- Primary document
- https://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/fdmt-20251231.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for 4D Molecular Therapeutics, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $85.2M | - | - |
| Operating Income | $-159.5M | - | - |
| Net Income | $-140.1M | - | - |
| Eps Basic | -2.42 | - | - |
| Eps Diluted | -2.42 | - | - |
| Cash And Equivalents | $60.2M | - | - |
| Total Assets | $566.7M | - | - |
| Total Liabilities | $61.0M | - | - |
| Shareholders Equity | $505.7M | - | - |
| Operating Cash Flow | $-109.1M | - | - |
| Capital Expenditures | $536,000 | - | - |